YesPress Dossier · Company
Medisafe®
The pillbox that grew up into a platform.
Above: the little orange icon that sits on 13 million phones and nags, kindly, until the pill is taken.
The pillbox that grew up into a platform.
Above: the little orange icon that sits on 13 million phones and nags, kindly, until the pill is taken.
It is 8:00 a.m. somewhere, and a phone buzzes. Not an email, not a like - a small orange nudge that says it is time for the morning dose. The person sighs, opens the cap, swallows, and taps a checkmark. Multiply that quiet moment by roughly 13 million people and 4 billion doses, and you have the thing Medisafe actually built. Not an app, exactly. A habit, rented out at scale.
Today Medisafe is two businesses wearing one logo. To patients, it is a free virtual pillbox that remembers what they would rather forget. To pharmaceutical companies, it is an engagement engine - Medisafe Maestro - that turns the messy, deeply human problem of "people stop taking their medicine" into something measurable, programmable, and improvable. The company sells the second to fund the first.
Medication non-adherence is the rare crisis everyone agrees on and almost nobody fixes. Patients mean well. Doctors prescribe correctly. Pharmacies fill the bottle. And then life happens - the schedule is complicated, the side effects are annoying, the refill lapses - and the carefully designed therapy quietly stops working because it is sitting in a cabinet.
The bill for all this forgetting is enormous: by common estimates, non-adherence drives somewhere between $100 and $300 billion in avoidable U.S. healthcare costs every year, plus a long tail of preventable hospitalizations. It is, in other words, a behavioral problem disguised as a clinical one. Reminders alone don't solve it - if they did, the alarm clock would have cured diabetes decades ago.
In 2012, the Shor family had a scare. The father of Omri and Rotem Shor accidentally took a double dose of insulin - the kind of ordinary mistake that can turn fatal in an afternoon. He recovered. The brothers did not let the lesson go.
Omri, the marketer, and Rotem, the software developer, started building in Haifa, Israel. Their bet was unfashionable at the time: that the fix for a medical problem was not a better drug or a smarter doctor, but better behavior design on the device already in everyone's pocket. They shipped a free app - a virtual pillbox with push reminders, refill alerts, and a feature called "Medfriend" that pings a family member when a dose is missed. Turning your sister into a backup alarm clock is not glamorous engineering. It works.
A $1M seed round in 2013 from lool Ventures and Triventures gave the brothers room to find out whether millions of strangers wanted the same safety net. They did.
The free app is the front door. Behind it sits the more interesting machine. Medisafe's Just-in-Time Interventions engine - JITI - watches the patterns: which message, at which hour, in which tone, makes a particular person more likely to take a dose. Then it adjusts. The pill reminder you get on a Tuesday is not the one your neighbor gets, because you are two different people with two different ways of quietly giving up.
For pharmaceutical companies, all of that behavioral plumbing is packaged into Maestro: a way to design, brand, and run patient-support journeys across drugs and markets without hiring an engineering team for each campaign. Adherence, persistence, refills, financial assistance, caregiver support - the unglamorous logistics of staying on a therapy - become things a brand manager can configure.
Free virtual pillbox: personalized reminders, refill and interaction alerts, and "Medfriend" caregiver pings.
No-code enterprise platform for pharma to design and run personalized patient journeys at scale.
Behavioral AI that learns the timing and message most likely to keep each patient on therapy.
Adherence, persistence, access, financial assistance, and clinical-trial support tools for partners.
Plenty of health apps promise engagement. Medisafe's case rests on volume and on who is willing to pay for it. The patient side proves people want the tool; the pharma side proves the tool does something a balance sheet can see.
Bars scaled for comparison, not to a single shared axis. Sources: Medisafe, PR Newswire, Tracxn, Built In Boston.
The 2021 Series C is the tell. When Sanofi Ventures leads a $30M round - alongside ALIVE, Merck Ventures, 7wire, Octopus, Pitango and a crowd of others - it is a pharma giant deciding that adherence is infrastructure worth owning a piece of. Cris De Luca of Sanofi Ventures and David Klein of ALIVE took board seats. The patients get a free app; the industry gets a measurable lever on revenue. Both sides, oddly, are happy.
Strip away the platform language and Medisafe's mission is small and human: help people stay on the medicine that keeps them well, and lower the staggering cost of the doses that go untaken. The company frames it in the vocabulary of pharma - adherence, persistence, patient journeys - but underneath is the same instinct that started it. Somebody you love forgets a dose. You build the thing that catches it.
That is why the consumer app stays free even as the enterprise side pays the bills. The mission only works if the patient never has to choose between a reminder and a subscription. Behavioral science, personalization, and a phone that already lives in your hand - that is the whole toolkit, pointed at the unglamorous goal of making the right behavior the easy one.
The pressure is building. Drug pricing is under political scrutiny, with proposals to slash U.S. prices that would force pharma to prove every dollar of patient support actually works. In a world where a manufacturer has to justify the value of a therapy, the company that can show - with data - that more patients stayed on it becomes very useful, very fast. Adherence stops being a nice-to-have and becomes the receipt.
Medisafe's competitors - AllazoHealth, Wellth, Mango Health, DrFirst and others - are circling the same gap. What Medisafe brings is a decade of behavioral data, a large installed base of patients who already trust the orange icon, and a no-code platform that lets pharma teams act on all of it. The bet the Shor brothers made in 2012 - that behavior, not just chemistry, decides whether medicine works - is looking less like a hunch and more like the industry's next requirement.
Watch interviews and product demos on the Medisafe YouTube channel — including founder talks and Maestro walkthroughs.